Changes in Kidney Function Following Heart Failure Treatment: Focus on Renin-Angiotensin System Blockade

Heart Failure Clinics

Volumn 4, Issue 4, 2008, Pages 425-438

  Blankstein, Ron ^a   Bakris, George L ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; EPROSARTAN; FOSINOPRIL; HYDRALAZINE; IRBESARTAN; LISINOPRIL; LOOP DIURETIC AGENT; LOSARTAN; MOEXIPRIL; NITRATE; OLMESARTAN; PERINDOPRIL; PLACEBO; QUINAPRIL; RAMIPRIL; SPIRONOLACTONE; TELMISARTAN; TRANDOLAPRIL; VALSARTAN;

ADD ON THERAPY; ANAMNESIS; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; DIURETIC THERAPY; DRUG WITHDRAWAL; HEART FAILURE; HEMODYNAMICS; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; KIDNEY FUNCTION; LABORATORY TEST; LOW DRUG DOSE; MONOTHERAPY; MORBIDITY; MORTALITY; RECEPTOR BINDING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; FEMALE; HEART FAILURE; HUMANS; KIDNEY; KIDNEY DISEASES; MIDDLE AGED; RENIN-ANGIOTENSIN SYSTEM;

EID: 50149119316     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2008.03.007     Document Type: Review

References (44)

1. Jessup M., and Brozena S. Heart failure. N Engl J Med 348 20 (2003) 2007-2018
2. Hunt S.A., Abraham W.T., Chin M.H., et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112 12 (2005) e154-e235
3. Taylor A.L., Ziesche S., Yancy C., et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351 20 (2004) 2049-2057
4. Zisman L.S., Abraham W.T., Meixell G.E., et al. Angiotensin II formation in the intact human heart: predominance of the angiotensin-converting enzyme pathway. J Clin Invest 96 3 (1995) 1490-1498
5. Sharma J.N. Does the kinin system mediate in cardiovascular abnormalities? An overview. J Clin Pharmacol 43 11 (2003) 1187-1195
6. Garg R., and Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure: Collaborative Group on ACE Inhibitor Trials. JAMA 273 18 (1995) 1450-1456
7. Flather M.D., Yusuf S., Kober L., et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 355 9215 (2000) 1575-1581
8. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS): the CONSENSUS Trial Study Group. N Engl J Med 316 23 (1987) 1429-1435
9. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure: the SOLVD investigators. N Engl J Med 325 5 (1991) 293-302
10. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions: the SOLVD investigators. N Engl J Med 327 10 (1992) 685-691
11. Pfeffer M.A., Braunwald E., Moye L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. The SAVE investigators. N Engl J Med 327 10 (1992) 669-677
12. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure: the Acute Infarction Ramipril Efficacy (AIRE) Study investigators. Lancet 342 8875 (1993) 821-828
13. Kober L., Torp-Pedersen C., Carlsen J.E., et al. A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction: Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 333 25 (1995) 1670-1676
14. Jong P., Demers C., McKelvie R.S., et al. Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. J Am Coll Cardiol 39 3 (2002) 463-470
15. Granger C.B., McMurray J.J., Yusuf S., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting enzyme inhibitors: the CHARM-Alternative trial. Lancet 362 9386 (2003) 772-776
16. Lee V.C., Rhew D.C., Dylan M., et al. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med 141 9 (2004) 693-704
17. Pitt B., Segal R., Martinez F.A., et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349 9054 (1997) 747-752
18. Pitt B., Poole-Wilson P.A., Segal R., et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 355 9215 (2000) 1582-1587
19. McKelvie R.S., Yusuf S., Pericak D., et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD pilot study investigators. Circulation 100 10 (1999) 1056-1064
20. Cohn J.N., and Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 23 (2001) 1667-1675
21. McMurray J.J., Ostergren J.., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting enzyme inhibitors: the CHARM-Added trial. Lancet 362 9386 (2003) 767-771
22. Pfeffer M.A., Swedberg K., Granger C.B., et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362 9386 (2003) 759-766
23. Yusuf S., Pfeffer M.A., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362 9386 (2003) 777-781
24. Bhakta S., and Dunlap M.E. Angiotensin-receptor blockers in heart failure: evidence from the CHARM trial. Cleve Clin J Med 71 8 (2004) 665-673
25. Kunz R., Friedrich C., Wolbers M., et al. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 148 1 (2008) 30-48
26. Phillips C.O., Kashani A., Ko D.K., et al. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med 167 18 (2007) 1930-1936
27. Juurlink D.N., Mamdani M.M., Lee D.S., et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351 6 (2004) 543-551
28. Cicoira M., Zanolla L., Franceschini L., et al. Relation of aldosterone "escape" despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 89 4 (2002) 403-407
29. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study investigators. N Engl J Med 341 10 (1999) 709-717
30. Masoudi F.A., Rathore S.S., Wang Y., et al. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. Circulation 110 6 (2004) 724-731
31. Echemann M., Zannad F., Briancon S., et al. Determinants of angiotensin-converting enzyme inhibitor prescription in severe heart failure with left ventricular systolic dysfunction: the EPICAL study. Am Heart J 139 4 (2000) 624-631
32. de Groote P., Isnard R., Assyag P., et al. Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey. Eur J Heart Fail 9 12 (2007) 1205-1211
33. Lee D.S., Tu J.V., Juurlink D.N., et al. Risk-treatment mismatch in the pharmacotherapy of heart failure. JAMA 294 10 (2005) 1240-1247
34. Hillege H.L., Nitsch D., Pfeffer M.A., et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 113 5 (2006) 671-678
35. Lee W.H., and Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 73 2 (1986) 257-267
36. Gambassi G., Lapane K.L., Sgadari A., et al. Effects of angiotensin-converting enzyme inhibitors and digoxin on health outcomes of very old patients with heart failure: SAGE Study Group (Systematic Assessment of Geriatric drug use via Epidemiology). Arch Intern Med 160 1 (2000) 53-60
37. Havranek E.P., Abrams F., Stevens E., et al. Determinants of mortality in elderly patients with heart failure: the role of angiotensin-converting enzyme inhibitors. Arch Intern Med 158 18 (1998) 2024-2028
38. Ahmed A., Kiefe C.I., Allman R.M., et al. Survival benefits of angiotensin-converting enzyme inhibitors in older heart failure patients with perceived contraindications. J Am Geriatr Soc 50 10 (2002) 1659-1666
39. Knight E.L., Glynn R.J., McIntyre K.M., et al. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD). Am Heart J 138 5 Pt 1 (1999) 849-855
40. Palmer B.F. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what to do if the serum creatinine and/or serum potassium concentration rises. Nephrol Dial Transplant 18 10 (2003) 1973-1975
41. Apperloo A.J., de Zeeuw D., and de Jong P.E. A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 51 3 (1997) 793-797
42. Bakris G.L., and Weir M.R. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?. Arch Intern Med 160 5 (2000) 685-693
43. Bakris G.L., Siomos M., Richardson D., et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int 58 5 (2000) 2084-2092
44. Chobanian A.V., Bakris G.L., Black H.R., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289 19 (2003) 2560-2572